3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Glioblastoma
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Renal Insufficiency
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Lung Neoplasms
1
Liver Failure
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Rituximab
40
Cyclophosphamide
36
Prednisone
24
Doxorubicin
23
Magnetic Resonance Spectroscopy
20
Vincristine
19
Gemcitabine
18
Specimen Handling
17
Lenalidomide
17
Biopsy
15
Oxaliplatin
14
polatuzumab vedotin
13
obinutuzumab
11
glofitamab
11
ibrutinib
10
fludarabine
8
Etoposide
8
Dexamethasone
8
CT-P10
8
prednylidene
7
deltacortene
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
7
venetoclax
6
tafasitamab
6
pembrolizumab
6
Prednisolone
6
fludarabine phosphate
5
acalabrutinib
5
R-CHOP protocol
5
Cyclosporine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
veliparib
×
90 days
×
Clear all
No trials found.